2024. Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial. SKIN The Journal of Cutaneous Medicine. 8, 2 (Mar. 2024), s383. DOI:https://doi.org/10.25251/skin.8.supp.383.